Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proteomic and genetic markers of oxaliplatin-induced neurotoxicity in colorectal cancer
2007-001287-75Phase 2Active
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Apr 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Genetic and proteomic markers of neurotoxicity. Started Apr 2007; status: active.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-001287-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001287-75.